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Allergic bronchopulmonary mycosis (ABPM) is a known complication of asthma and can result in progressive lung
damage, respiratory failure and death. Asthma is a common disease in Saudi Arabia and until now the prevalence
of ABPM has not been investigated. The aim of this study was to estimate the period prevalence of ABPM due to
Aspergillus and Candida in patients with asthma. The setting was an outpatient pulmonary clinic at a university
hospital in the central region of Saudi Arabia. Two hundred and sixty-four consecutive patients with asthma (150
or 57% females) were evaluated. All patients were screened for ABPM with skin prick test (SPT) using a panel of
fungal antigens. Those with positive skin reactions had further clinical, immunological, respiratory and radiological
assessment. ABPM was diagnosed by the presence of a minimum of five of the major criteria suggested by
Rosenberg in 1977. Of the 264 patients, 62 (23%) had a positive SPT for at least one fungal allergen, of whom 44
(71%) were females (P=0?01). Seven patients (six females) were diagnosed with ABPM due to Aspergillus and (or)
Candida species. Therefore, we estimate the period prevalence of ABPM to be 2?7% (95% confidence interval 1?3–
5?4%). A. niger was the commonest fungal species isolated in our group. In conclusion, ABPM is not uncommon in
Saudi Arabia and females seem to be more at risk. Because asthma is common, physicians need to have high index
of suspicion for this disease and pursue the diagnosis with the appropriate tests.
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Fungi are common allergens in asthma and are widely
prevalent both indoors and outdoors (1–3). One conse-
quence of exposure to these allergens is the well-recognized
syndrome allergic bronchopulmonary mycosis (ABPM).
ABPM is thought to result from a hypersensitivity reaction
and is characterized by a number of clinical, immunological
and radiological features, which were described by Rosen-
berg (4). If not recognized, it can progress to lung
destruction, respiratory failure and death, therefore it is
prudent to exclude ABPM in patients with asthma (5,6).
ABPM was first described in the U.K. in 1952 (7) and
was related to Aspergillus (ABPA). Subsequently, this
syndrome was reported in many countries and related to
a wide range of fungi (8). In Europe and U.S.A. theReceived 7 April 2000 and accepted in revised form 25 January
2001.
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28%, depending on the methods and the patient population
studied (9–12). To our knowledge, no surveys of ABPM
were done in the Middle East, including countries where
asthma is common, such as Saudi Arabia. Therefore, this
study was carried out to ascertain the period prevalence of
ABPM secondary to Aspergillus and Candida in patients
with asthma attending chest clinics at our hospital.
Materials and methods
The study was conducted in King Khalid University
Hospital, Riyadh, which is located in the central province
(Najd), Saudi Arabia. This region is mainly a desert about
400 km inland. The hospital serves both as a general
hospital and a tertiary referral centre.
CLINICAL CHARACTERSTICS
Patients with asthma attending the outpatient pulmonary
clinic from 15 February 1997 to 28 July 1998 were
evaluated after consenting to the study. The study was# 2001 HARCOURT PUBLISHERS LTD
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Medicine Research Council. The diagnosis of asthma was
confirmed clinically by the treating pulmonologist and by
the demonstration of airway obstruction and significant
response to bronchodilator on testing with spirometry. For
the minority of patients who could not perform spirometry,
peak expiratory flow rate was used. Skin prick test (SPT)
was used for screening patients for ABPM, as it is believed
to be highly sensitive (5). Pregnant women and patients
taking continuous oral steroids were excluded from the
study, since these conditions may interfere with the results
of some of the tests. Patients on anti-histamines were re-
tested after stopping them for 4–6 weeks. All patients with
positive SPT underwent further immunological, microbio-
logical and radiological assessment as detailed below.
ABPM was defined by the presence of a minimum of five
of the following seven major criteria originally proposed by
Rosenberg (4), with the addition of specific IgE (5):
1. Asthma
2. Peripheral blood eosinophilia
3. Immediate skin test reactivity for Aspergillus or
Candida antigens
4. Elevated total serum immunoglobulin E (IgE) (above
1000 kU l71) and (or) specific IgE
5. Positive serum precipitins (IgG) against Aspergillus or
Candida antigens
6. Fleeting or fixed pulmonary shadows
7. Central bronchiectasis.
IMMUNOLOGICAL INVESTIGATIONS
Skin prick test (SPT)
The skin prick test was performed in all patients using 17
fungal antigens. The panel included: Aspergillus fumigatus,
A. niger, A. versicolor, A. clavatus, A. repens, Alternaria,
Cladosporium, Rhizopus, Penicillium, Mucor, Trichophyton,
Candida, Herbarum, Phoma, Fusarium, mould I and mould
II (a mixture of fungal allergens), histamine (positive
control), and negative control. The technique for SPT was
followed as described by Pepys (13). Skin test extracts
‘Soluprick’ were purchased from ALK Laboratories,
Horsholm, Denmark. Immediate reactions were read after
10–15min and were interpreted as positive only if wheal
and flare measured 3mm or more with a positive histamine
control.
Total, specific IgE measurement and serum
precipitins
Total IgE measurement. Blood was obtained by
venipuncture from all patients. The sample was allowed
to clot and the serum separated by centrifugation. Speci-
mens were kept at 7208C until assayed. The Pharmacia
CAP System IgE fluoroenzyme immunoassay (FEIA)
method was used. This is an in-vitro test system for thequantitative measurement of circulating total IgE in human
blood samples. The results were recorded in kU l71.
Specific IgE measurement. The Pharmacia CAP
System RAST FEIA method was used. This is an in-vitro
test, which measures the concentration of circulating
allergen-specific IgE in human blood samples. All serum
samples were tested against a standard panel of fungal
allergen which included: Aspergillus fumigatus, Alternaria,
Cladosporium, Rhizopus, Penicillium, Mucor, Candida,
Fusarium and Phoma. Values more than 0?70 kU l71 were
considered positive. The test for measuring total and
specific IgE was performed according to the manufacturer’s
procedural guidelines.
Serum precipitins. Sera of patients with positive skin
reactions were tested for presence of precipitating anti-
bodies against Aspergillus and Candida antigens using
immunodiffusion and counter-immunoelectrophoresis.
The antigens used (by Immunomycologics, Norman,
Oklahoma, U.S.A.) were Aspergillus polyvalent antigen
(containing antigens of Aspergillus fumigatus, A. flavus and
A. niger), monovalent antigens of A.terreus, A. nidulans,
and Candida spp. antigen.
Eosinophil count. Eosinophil count of equal or more
than 400 ml71 was used to indicate significant eosinophilia.
MICROBIOLOGICAL STUDIES
Direct microscopy and culture
Sputa were collected of patients with positive SPT who
were able to expectorate specimens. Smears were made and
stained with Giemsa stain, then examined microscopically
for fungal elements. The specimen was cultured on each of
Sabouraud’s dextrose agar and Sabouraud’s dextrose agar
with chloramphenicol and incubated at room temperature
(26+18C) for up to 4 weeks before reporting as negative if
no growth occurred. Cultures were examined periodically
to detect any growth, and when growth was found, they
were subcultured onto Sabouraud’s dextrose agar slopes
and identified using standard mycological methods.
PULMONARY FUNCTION TESTS
Spirometry was performed according to the American
Thoracic Society (ATS) recommendations (14). Measure-
ments included the forced expiratory volume in 1 sec
(FEV1) and forced vital capacity (FVC), and were
expressed as percentage of predicted values.
RADIOLOGICAL STUDIES
Chest radiographs (CXR) were performed for all patients
with positive SPT. A high resolution computed tomography
(HRCT) scan of the chest was done for patients with
suspicious findings on CXR (e.g. mild bronchial dilatation
or thickening). HRCT was done from the apex to the base
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thorax of the patients) or limited (with 1?5620mm cuts
from the aortic arch to the diaphragm and six cuts on
expiration). All radiological material was reviewed by one
pulmonary radiologist who was not aware of the results of
the other investigations. The diagnostic findings for ABPM
included central bronchiectasis (CB) and fleeting pulmon-
ary shadows (FS) that are not explained by other causes
such as infection, infarction or autoimmune diseases.
Results
During the study period 273 consecutive patients with
asthma were evaluated. Nine patients were excluded (six
pregnant women and three on chronic steroid therapy),
leaving 264 patients for further evaluation.
CLINICAL CHARACTERISTICS
A total of 264 patients were screened with the skin prick test
(SPT). The age of the patients ranged between 7 and 93
years, mean age and standard deviations were 38+17 years.
One hundred and fifty (56.8%) were females and 114
(43?2%) were males. Two hundred and two patients
(76?5%) had negative SPT and 62 (23?5%) had positive
SPT to one or more fungal allergen. In the group with
positive SPT 44 (71%) were females, as opposed to 106
(52?5%) in the group with negative SPT (P=0?01, Table 1).
Before assessment, 50 (81%) of patients with positive SPT
and 101 (50%) of patients with negative SPT were taking
consistently inhaled corticosteroids (P50.001). There were
few smokers (none in patients with positive SPT and four in
patients with negative SPT). Ex-smokers were one and two
in the two groups, respectively.
The clinical features of patients according to the skin test
result are shown in Table 1. Cough was the only symptom
showing a statistically significant difference. History of
atopy (allergic rhinitis, conjunctivitis or dermatitis) was
slightly higher in patients with positive SPT but the
difference was not statistically significant.TABLE 1. Clinical characteristics of the patients
Parameter Patients with positive
skin prick test (%), n=62
Females 71
SOB* 84
Cough 98
Sputum 70
Sputum casts 16
Wheeze 93
Atopy{ 66
On inhaled steroids 81
*Shortness of breath at rest or on exertion.
{Atopy: history of allergic rhinitis, conjunctivitis or dermatitis.IMMUNOLOGICAL INVESTIGATIONS
Skin prick test
Sixty-two (23%) out of 264 patients showed positive SPT to
one or more of the allergens tested. Details are available for
53 patients (Table 2) and were as follows: 16 patients (30%)
reacted to the mould I extract; 16 patients (30%) to
Candida; 15 patients (28%) to Aspergillus niger; 14 patients
(26%) to Alternaria; 12 patients (23%) to Aspergillus
fumigatus; 12 patients (23%) to mould II; seven patients
(13%) each to A. versicolor, A. clavatus, A. repens,
Cladosprium, Penicillium; two patients (4%) to Trichophy-
ton; and one (2%) to Mucor. There were no reactions to
Herbarum, Phoma and Fusarium. Details of the remaining
nine patients could not be located, although it was known
for certain that they had positive SPT.
Total, specific IgE measurement and serum
precipitins
Total IgE. Total IgE ranged from 2?88 to41000 kU l71,
mean 368+SD 338. Fourteen patients had values above
1000 kU l71.
Specific IgE. Details are available for 54 patients
(Table 2). Twenty patients (37%) had a positive specific
IgE test to at least one fungal allergen. Candida and
Alternaria were the most prominent allergens showing
positive reactions. The frequency of specific IgE antibodies
to different allergens is as follows: Candida, 15 patients
(28%); Alternaria, 14 patients (26%); A. fumigatus, 12
patients (22%); Cladosporium, 11 patients (20%); Rhizopus
and Fusarium, 10 patients (19%) each; and Penicillium,
Phoma and Mucor, nine patients (17%) each. Unfortu-
nately, specimens from the remaining eight patients were
not received by the laboratory. However, even if these
patients were assumed to have positive results, none of
them would have had sucient other positive criteria for
the diagnosis of ABPM.Patients with negative
skin prick test (%), n=202
P-value
52?5 0?01
89 0?3
86 0?0002
60 0?1
16 0?9
86 0?1
56 0?2
50 50?001
TABLE 2. Results of skin prick test, specific IgE and cultures of the common fungi*
Test Skin prick test Specific IgE Fungal growth from
respiratory secretions
Number 53 54 35
Aspergillus niger 15 (28) NA 5 (14)
Aspergillus fumigatus 12 (23) 12 (22) 1 (3)
Candida spp. 16 (30) 15 (28) 15 (43)
Alternaria 14 (26) 14 (26) 0
Cladosporium 7 (13) 11 (20) 0
*Values between parenthesis indicate percentage.
NA=not available.
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eight patients (13%) had positive serum precipitins for
Aspergillus species-specific antigen and two patients (3%)
had positive results for Candida antigen. One patient had
positive serum precipitins for both Candida and Aspergillus
antigens.
Eosinophil count
The range of the eosinophil counts was 10–2580 ml71.
Seventeen patients (27%) had more than 400 eosino-
phils ml71 in their peripheral blood.
MICROBIOLOGICAL STUDIES
Of the group of patients with positive SPT, 35 patients
managed to provide sputum for fungal studies (Table 2).
Sputum smears for fungi showed hyphae in 16, yeast in two
and were negative in the remaining specimens. Culture
results for Aspergilli were as follows: five A. niger, and one
each of A. fumigatus, A. flavus, A. terreus and Aspergillus
spp. in patients with ABPA (Table 2). A. niger was isolated
from four patients and A. terreus from one patient. A.
fumigatus was not isolated from any patient with ABPA.
C. albicans was cultured from 13 patients, C. glabrata
and C. parapsilosis from one patient each. C. albicans was
associated with Aspergillus in two patients with a positive
specific IgE (Table 3, patient nos 1 and 2). C. albicans was
also isolated solely from one patient but with a negative
specific IgE and SPT, which indicates that a pathogenic role
is unlikely.
PULMONARY FUNCTION TESTS
Two hundred and eleven patients had spirometry (46 with
positive SPT and 165 with negative SPT). Patients with
positive SPT had lower FEV1 and FVC than patients with
negative SPT (P-value for FEV1=0?0016 and for
FVC=0?0037) as shown in Table 4.RADIOLOGICAL STUDIES
Chest radiographs of the 62 patients with positive SPT
showed the following: 42 were normal, 17 showed non-
diagnostic abnormalities, three showed fleeting shadows
and one showed CB. Patients with abnormal CXR went on
for HRCT scan, which showed CB in four patients.
PATIENTS WITH ABPM
Out of the 264 asthmatic patients screened with SPT, 62
(23%) had positive skin test reactions. Seven patients
fulfilled five or more of the major criteria for the diagnosis
of ABPM (Table 3), i.e. a period prevalence of 2?7%, 95%
confidence interval 1?3–5?4% (15). Of those patients six
were females and one only was male. Patients 1, 2 and 7
were referred from coastal cities in the south-west of Saudi
Arabia, and the remainder were from central Arabia.
Discussion
To our knowledge, this is the first survey of ABPM in
patients with asthma in the Middle East. Studies have
shown that fungal allergens are prevalent both in the indoor
and outdoor environment in Riyadh (2), as well as positive
skin reactions to fungi in asthmatic patients (3). Despite
this, only one series of 10 patients with ABPA was reported
in a retrospective study in Saudi Arabia from 1984 to 1994
(8). It was thought that the low natural humidity in central
Arabia (540%), which can inhibit the growth of fungi,
might have contributed to the rarity of this syndrome (8).
This study shows period prevalence close to 3% for ABPM
due to Aspergillus and Candida, suggesting that the disease
is not uncommon but more likely overlooked among
asthma patients attending our outpatient clinics.
In Western countries the reported frequencies ranged
between 1 and 28% depending on the patient population
and methods of the study. For example, in the U.K. an
earlier study found a prevalence of 11% (9). The criteria
used to define ABPA in that study included: asthma,
eosinophilia, a positive skin reaction to A. fumigatus and a
TABLE 3. Clinical profile and criteria of the patients with allergic bronchopulmonary mycosis (ABPM)
Initials FL FA MSH HM HO NSH BGH
Sex Female Male
Age (years) 28 50 15 27 15 58 15
Presenting
picture
Chronic
mild to
moderate
asthma
since
childhood,
Aspergillus
sinusitis
Sputum casts,
cough,
recurrent
atelectasis,
recent asthma
Mild
asthma
since
childhood,
urticaria,
dermatitis,
rhinitis
Cough,
wheeze,
sputum,
recent
asthma
Mild
asthma for
10 years,
rhinitis
Severe
asthma
for 22 years,
rhinitis
Mild to
moderate
asthma for 6
years
Residence Jizan Jizan Najd Najd Najd Najd Sebia
Eosinophil
count (m l71)
690 390 610 640 500 830 640
Chest radio-
graph
FS FS FS FS NS NS CB
CT scan of
chest
CB, MI NS NS CB, MI NS CB, MI CB, MI
Immediate
skin test
A. fumigatus
A. niger
Alternaria
Candida
Mould II
A. fumigatus
Penicilium
A. niger
Mould I
Alternaria
Mould I
A. fumigatus
A. fumigatus A. fumigatus
A. niger
Repens
mould I and
II
A. niger
A. fumigatus
Total IgE
(kU l71)
42000 42000 42000 327 1132 42000 1020
Specific IgE
(kU l71)
All + for all
except Mucor,
Pencillium
+for all
except
Mucor
Neg. Rhizopus,
mucor
+for all A. fumigatus
Serum pre-
cipitens
respiratory
secretions*
Asp.+ Neg. Asp.+ Neg. Asp.+ Neg. Asp.+
Smear/
hyphae
+ + Neg. Neg. + + +
Culture A. niger
C. albicans
A. terreus
C. albicans
Neg. A. niger C. albicans A. niger A. niger
*Sputum except in cases FA and HM who had bronchial lavage.
Asp: Aspergillus; CB: central bronchiectasis; CT: computed tomography; FS: fleeting shadows; MI: mucoid impaction; Neg:
negative; NS: non-specific.
Jizan and Sebia: south-west costal Saudi Arabia; Najd: central Arabia.
TABLE 4. Spirometric results
Skin prick test parameter*
spirometry Positive
( n=46)
Negative
( n=165)
P-value
FEV1 % 72?4 81?6 0?0016
FVC % 79 88 0?0037
*Expressed as percentage of predicted value.
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(10) found the period prevalence of ABPM due to
Aspergillus and Candida to be just over 1% in an outpatient
clinic between 1985 and 1988. They screened patients with
asthma and eosinophilia or unexplained pulmonary infil-
trates requiring a minimum of four criteria that included a
positive serology to A. fumigatus or C. albicans. In the
U.S.A. two surveys of ABPA were done on asthmatic
patients with a positive skin reaction i.e. following
methodology similar to the one used in our study. More
strict criteria were used that included specific serological
assays to Aspergillus and the radiological finding of central
346 A. F. AL-MOBEIREEK ET AL.bronchiectasis. In the first, Greenberger and Patterson
reported a prevalence of 6% (11). Surprisingly, a much
higher rate of 28% was found by Schwartz and Green-
berger in the second survey in Cleveland, Ohio, U.S.A. (12).
They attributed this to the more rigorous and diligent
testing they followed. These compare to 11% in our survey
(i.e. seven out of 62 of our patients with positive skin tests).
Differences in methodology and definitions make com-
parison between these studies dicult. Recent surveys have
taken advantage of the more specific and sensitive
serological and radiological testing allowing more accuracy
in the diagnosis. The results of our survey, which adopted
methodology similar to the U.S. surveys, suggest that the
disease is not uncommon in central Arabia. It is important,
therefore, to promote physicians’ awareness to ABPM.
More obstacles follow when trying to establish the
diagnosis. A number of criteria are required and these
may not be all present at the point of the assessment during
a ‘quiescent’ phase (5). Moreover, ABPM activity may not
be evident symptomatically (5). Therefore we think that the
true period prevalence rate is underestimated. Vigilance is
needed when following patients especially those known to
have some positive criteria (three or four). Another
diculty is the acquisition of the specific serological tests
and the proper antigen for skin testing. Most of the
available serological tests and skin extracts are specified for
A. fumigatus, the species implicated in the classical
descriptions of the disease. By contrast, A. niger was more
frequently isolated in our study. Misdiagnosis may occur if
the proper antigens are not used, even though some cross-
reactivity exists. We used extracts made from species that
were shown to be prevalent locally. Physicians in remote
and less privileged hospitals may experience diculties in
obtaining resources and expertise to facilitate the diagnosis.
Pitfalls that can lead to misdiagnosis were discussed in
detail by Schwartz and Greenberger (12).
It is interesting to notice that far more females were
sensitized to fungal allergens, and also more had ABPM.
Women in the reproductive years are thought to have
higher rates of skin test reactivity than men (16). This age-
specific sex difference is evident in this study as most of the
patients fell within this age range. Previous studies have
shown conflicting results. ABPM was more frequent in
females in the series reported by Donnelly et al. from
Ireland (10) and from a study of cystic fibrosis patients in
U.S.A. (17). However, one retrospective British series had
more males (18). Another noteworthy observation is that
patients with positive skin tests had poorer lung function
than those with negative tests, confirming the results of the
Cleveland–London study (1). There were significantly more
patients with positive skin test on inhaled steroids, which
also supports the observation that this group had more
severe asthma. Smoking was too uncommon among our
patients to account for such a difference.
As mentioned above, although A. fumigatus received
more emphasis in previous studies as having a more
pathogenic role, A. niger was more predominant in this
study. This may be explained by the higher prevalence of
this fungus in the warm and arid climate. Isolation of this
fungus in some of the cases may be merely the result ofcontamination. In our series Candida spp. is probably
implicated in two patients. Some cases may be due to other
fungi, as evident by the high frequency of positive skin tests
and specific IgE to the panel of fungal allergens tested.
ABPM due to these fungi could not be proven because the
specific serological tests were not available commercially.
Physicians should be alert to this possibility when the usual
tests (such as eosinophilia, elevated serum IgE, and
radiological signs) are positive but tests to Aspergillus or
Candida are negative.
In conclusion, ABPM is not uncommon in this study
from a university hospital in the central part of Saudi
Arabia. Since asthma is a common disease, clinicians need
to maintain a high index of suspicion for ABPM and keep
in mind its diverse manifestations. Advances in the more
specific serological and radiological investigations should
facilitate the diagnosis, but such tests should include a wide
range of the locally prevalent fungal species. Studies on the
prevalence in other areas of Arabia would be interesting,
particularly the south-western coastal areas.
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